Physician profile
Steven Daniel Factor
NPI 1730472408
$67,794.96
in general payments reported to CMS, 2019-2025
65 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,765 · 2020: $1,310 · 2021: $10K · 2022: $15K · 2023: $19K · 2024: $4,364 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $5,573 · Consulting Fee: $2,250 · Education: $58.49 · Travel and Lodging: $20.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,556.25 |
| Food and Beverage | $5,572.50 |
| Consulting Fee | $2,250.00 |
| Education | $58.49 |
| Travel and Lodging | $20.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55,800.81 | 2021-2025 | |
| Pfizer INC. | $2,447.06 | 2023-2025 | |
| Allergan, INC. | $1,148.21 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $961.98 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
| Amgen INC. | $795.05 | 2019-2023 | Aimovig |
| Alexion Pharmaceuticals, INC. | $590.47 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $575.10 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Argenx US, INC. | $457.68 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Upsher-Smith Laboratories LLC | $423.06 | 2019-2022 | |
| Ucb, INC. | $290.45 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $286.37 | 2019-2020 | |
| Lundbeck LLC | $252.49 | 2019-2025 | Vyepti, Rexulti |
| Csl Behring | $209.05 | 2020-2025 | Hizentra |
| Biohaven Pharmaceuticals, INC. | $191.43 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $178.92 | 2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Factor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.